Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer

Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers

(2018) M. Naveed Shaik et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma

(2018) Johanna Bendell et al.   CLINICAL CANCER RESEARCH

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

(2018) Michael R. Savona et al.   CLINICAL CANCER RESEARCH

A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors

(2018) Hideki Ueno et al.   INVESTIGATIONAL NEW DRUGS

GANT-61 and GDC-0449 induce apoptosis of prostate cancer stem cells through a GLI-dependent mechanism

(2018) Wangxia Tong et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer

(2018) Sherona R. Sirkisoon et al.   ONCOGENE

Molecular modeling study on resistance of WT/D473H SMO to antagonists LDE-225 and LEQ-506

(2018) Jing Tu et al.   PHARMACOLOGICAL RESEARCH

Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma

(2018) Jennifer Teichman et al.   PLoS One

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results

(2018) Jorge E. Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells

(2017) Annelies Gonnissen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Deciphering structural stability and binding mechanisms of potential antagonists with smoothened protein

(2017) Noopur Sinha et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma

(2017) Audrey A. Jacobsen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study

(2017) J.T. Lear et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors

(2017) Julia E Neumann et al.   NATURE MEDICINE

Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration

(2017) Justine L. Lam et al.   XENOBIOTICA

Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells

(2017) Yoshikazu Koike et al.   Breast Cancer

Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas

(2017) Sachin Jain et al.   OncoTargets and Therapy

Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts

(2016) Naz Chaudary et al.   BRITISH JOURNAL OF CANCER

Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors

(2016) Varun Goel et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

(2016) Vikram Malhi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Arsenic trioxide induces Noxa-dependent apoptosis in rhabdomyosarcoma cells and synergizes with antimicrotubule drugs

(2016) Michael Torsten Meister et al.   CANCER LETTERS

Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors

(2016) Hironobu Minami et al.   CANCER SCIENCE

Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells

(2016) Nobuaki Fukushima et al.   CANCER SCIENCE

Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas

(2016) Mohd Wahid et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors

(2016) Michelle Quinlan et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment

(2016) Amy A. Lubik et al.   INTERNATIONAL JOURNAL OF CANCER

GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax

(2016) Kateřina Vlčková et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment

(2016) Jianlong Li et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma

(2016) Reinhard Dummer et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma

(2016) Ximena Bonilla et al.   NATURE GENETICS

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

(2016) Mario E. Lacouture et al.   ONCOLOGIST

A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma

(2016) Daniel W. Bowles et al.   ORAL ONCOLOGY

A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma

(2016) Andrew H. Ko et al.   PANCREAS

A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer

(2016) Johannes-Matthias Löhr et al.   PANCREATOLOGY

In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors

(2016) Monica Benvenuto et al.   Oncotarget

GLI1 inhibitor GANT61 exhibits antitumor efficacy in T-cell lymphoma cells through down-regulation of p-STAT3 and SOCS3

(2016) Lingyun Geng et al.   Oncotarget

Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression

(2016) Chih-Min Tang et al.   Oncotarget

The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo

(2016) Annelies Gonnissen et al.   Oncotarget

Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia

(2016) David A. Irvine et al.   Scientific Reports

Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma

(2016) Mina S. Ally et al.   JAMA Dermatology

Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer

(2015) M Zuo et al.   BRITISH JOURNAL OF CANCER

An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib

(2015) C. Danial et al.   CLINICAL CANCER RESEARCH

Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant

(2015) Yuji Shimizu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cutaneous adverse effects of targeted therapies

(2015) James B. Macdonald et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

GLI2 inhibition abrogates human leukemia stem cell dormancy

(2015) Anil Sadarangani et al.   Journal of Translational Medicine

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

(2015) Michael R Migden et al.   LANCET ONCOLOGY

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial

(2015) Nicole Basset-Seguin et al.   LANCET ONCOLOGY

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis

(2015) Koji Sasaki et al.   LEUKEMIA & LYMPHOMA

Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells

(2015) Armine Matevossian et al.   Molecular Cancer

Regulation of the oncoprotein Smoothened by small molecules

(2015) Hayley J Sharpe et al.   Nature Chemical Biology

The role of hedgehog signalling in skeletal health and disease

(2015) Benjamin A. Alman   Nature Reviews Rheumatology

Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells

(2015) Y-H Fan et al.   ONCOGENE

Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer

(2015) Murielle Mimeault et al.   Oncotarget

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study

(2015) Giovanni Martinelli et al.   Lancet Haematology

PDGFRα up-regulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation

(2015) Francesco Sabbatino et al.   Oncotarget

GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis

(2015) Ritesh K. Srivastava et al.   Oncotarget

Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure

(2014) Jo Jo Hai et al.   ANNALS OF HEMATOLOGY

Vismodegib

(2014) Amber E. Proctor et al.   ANNALS OF PHARMACOTHERAPY

Molecular modeling study on the dynamical structural features of human smoothened receptor and binding mechanism of antagonist LY2940680 by metadynamics simulation and free energy calculation

(2014) Qifeng Bai et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells

(2014) C D’Amato et al.   BRITISH JOURNAL OF CANCER

Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition

(2014) Marcel Kool et al.   CANCER CELL

Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers

(2014) M. Naveed Shaik et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors

(2014) A. J. Wagner et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

(2014) J. Goldman et al.   CLINICAL CANCER RESEARCH

A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

(2014) J. Rodon et al.   CLINICAL CANCER RESEARCH

Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease

(2014) Margaret McCusker et al.   EUROPEAN JOURNAL OF CANCER

Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumorsin vitroandin vivoby targeting overexpressed Gli1

(2014) Kornelius Kerl et al.   INTERNATIONAL JOURNAL OF CANCER

Open-Label, Exploratory Phase II Trial of Oral Itraconazole for the Treatment of Basal Cell Carcinoma

(2014) Daniel J. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic Trioxide

(2014) Gail J. Roboz et al.   JOURNAL OF CLINICAL ONCOLOGY

Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model

(2014) Ke-Zhi Zhang et al.   Journal of Hematology & Oncology

Hedgehog pathway as a potential treatment target in human cholangiocarcinoma

(2014) Dorothee Riedlinger et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Vismodegib-associated hepatotoxicity: A potential side effect detected in postmarketing surveillance

(2014) Daniel J. Ventarola et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth

(2014) V. T. Campbell et al.   MOLECULAR CANCER THERAPEUTICS

Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma

(2014) E Petrova et al.   ONCOGENE

Down-Regulation of Gli Transcription Factor Leads to the Inhibition of Migration and Invasion of Ovarian Cancer Cells via Integrin β4-Mediated FAK Signaling

(2014) Qi Chen et al.   PLoS One

Blocking Signaling at the Level of GLI Regulates Downstream Gene Expression and Inhibits Proliferation of Canine Osteosarcoma Cells

(2014) Mehdi Hayat Shahi et al.   PLoS One

Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs

(2014) Chong Wang et al.   Nature Communications

Arsenic Trioxide Inhibits the Hedgehog Pathway Which Is Aberrantly Activated in Acute Promyelocytic Leukemia

(2013) Dongguang Yang et al.   ACTA HAEMATOLOGICA

Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma

(2013) C. Danial et al.   BRITISH JOURNAL OF DERMATOLOGY

Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma

(2013) Winnie W. Lo et al.   CANCER

Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists

(2013) James Kim et al.   CANCER CELL

Smoothened Inhibition Leads to Decreased Proliferation and Induces Apoptosis in Esophageal Adenocarcinoma Cells

(2013) Ali H. Zaidi et al.   CANCER INVESTIGATION

Discovery of NVP-LEQ506, a Second-Generation Inhibitor of Smoothened

(2013) Stefan Peukert et al.   ChemMedChem

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma

(2013) M. Axelson et al.   CLINICAL CANCER RESEARCH

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

(2013) A. Jimeno et al.   CLINICAL CANCER RESEARCH

Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1-Positive Leukemia

(2013) S. Katagiri et al.   CLINICAL CANCER RESEARCH

Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant

(2013) Tsuyoshi Ishii et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling

(2013) Naokazu Ibuki et al.   INTERNATIONAL JOURNAL OF CANCER

Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma

(2013) Nataliya Razumilava et al.   JOURNAL OF HEPATOLOGY

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2013) Charles M. Rudin et al.   Journal of Thoracic Oncology

Structure of the human smoothened receptor bound to an antitumour agent

(2013) Chong Wang et al.   NATURE

Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling

(2013) Elissaveta Petrova et al.   Nature Chemical Biology

NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200

(2013) J. Fu et al.   NEURO-ONCOLOGY

Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer

(2013) E. S. Antonarakis et al.   ONCOLOGIST

Genistein attenuates cancer stem cell characteristics in gastric cancer through the downregulation of Gli1

(2013) DAYEON YU et al.   ONCOLOGY REPORTS

Arsenic Trioxide Prevents Osteosarcoma Growth by Inhibition of GLI Transcription via DNA Damage Accumulation

(2013) Shunsuke Nakamura et al.   PLoS One

NVP-LDE225, a Potent and Selective SMOOTHENED Antagonist Reduces Melanoma Growth In Vitro and In Vivo

(2013) Ahmad Jalili et al.   PLoS One

Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium

(2013) Sarah E. Wilkinson et al.   PROSTATE

The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway

(2013) Sherri Smith et al.   XENOBIOTICA

Arsenic trioxide inhibits viability of pancreatic cancer stem cells in culture and in a xenograft model via binding to SHH-Gli

(2013) Jin-bin Han et al.   OncoTargets and Therapy

Genistein decreases the breast cancer stem-like cell population through Hedgehog pathway

(2013) Panhong Fan et al.   Stem Cell Research & Therapy

Structure and function of the Smoothened extracellular domain in vertebrate Hedgehog signaling

(2013) Sigrid Nachtergaele et al.   eLife

Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: Modification of the core skeleton for improved solubility

(2012) Tomohiro Ohashi et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma

(2012) S. Blotta et al.   BLOOD

Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog–Gli1 pathway

(2012) Linlin Zhang et al.   CANCER LETTERS

A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients

(2012) E. Messing et al.   Cancer Prevention Research

Abstract 2819: Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling

(2012) Mark H. Bender et al.   CANCER RESEARCH

Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growthin vitroandin vivo

(2012) Malin Wickström et al.   INTERNATIONAL JOURNAL OF CANCER

Daily Dosing of Vismodegib to Steady State Does Not Prolong the Qtc Interval in Healthy Volunteers

(2012) Richard A. Graham et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer

(2012) A. D. Steg et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

(2012) Aleksandar Sekulic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model

(2012) M. J. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b

(2012) Maria Karlou et al.   PROSTATE

Hedgehog Inhibition With the Orally Bioavailable Smo Antagonist LDE225 Represses Tumor Growth and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Neoplasms

(2011) Volker Fendrich et al.   ANNALS OF SURGERY

Arsenite induces cell transformation by reactive oxygen species, AKT, ERK1/2, and p70S6K1

(2011) Richard L. Carpenter et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Hedgehog Overexpression Is Associated with Stromal Interactions and Predicts for Poor Outcome in Breast Cancer

(2011) S. A. O'Toole et al.   CANCER RESEARCH

Effects of the Hedgehog pathway inhibitor GDC-0449 on lung cancer cell lines are mediated by side populations

(2011) Fei Tian et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

(2011) R. A. Graham et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic-Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation

(2011) H. Wong et al.   CLINICAL CANCER RESEARCH

Topical Treatment of Basal Cell Carcinomas in Nevoid Basal Cell Carcinoma Syndrome with a Smoothened Inhibitor

(2011) Hans Skvara et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Genistein inhibited proliferation and induced apoptosis in acute lymphoblastic leukemia, lymphoma and multiple myeloma cellsin vitro

(2011) Wang Li et al.   LEUKEMIA & LYMPHOMA

Mechanisms and functions of Hedgehog signalling across the metazoa

(2011) Philip W. Ingham et al.   NATURE REVIEWS GENETICS

Efficacy and Safety of Short-Term Genistein Intervention in Patients with Localized Prostate Cancer Prior to Radical Prostatectomy: A Randomized, Placebo-Controlled, Double-Blind Phase 2 Clinical Trial

(2011) Bato Lazarevic et al.   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

Sonic Hedgehog Pathway Is Essential for Maintenance of Cancer Stem-Like Cells in Human Gastric Cancer

(2011) Zhou Song et al.   PLoS One

Inhibition of Hedgehog Signaling Antagonizes Serous Ovarian Cancer Growth in a Primary Xenograft Model

(2011) Christopher K. McCann et al.   PLoS One

Hedgehog Signaling Antagonist GDC-0449 (Vismodegib) Inhibits Pancreatic Cancer Stem Cell Characteristics: Molecular Mechanisms

(2011) Brahma N. Singh et al.   PLoS One

Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened

(2011) Michael J. Munchhof et al.   ACS Medicinal Chemistry Letters

TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH SINGLE-AGENT ARSENIC TRIOXIDE

(2011) Vikram Mathews et al.   Mediterranean Journal of Hematology and Infectious Diseases

Common Botanical Compounds Inhibit the Hedgehog Signaling Pathway in Prostate Cancer

(2010) A. Slusarz et al.   CANCER RESEARCH

Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance

(2010) Gerrit J. P. Dijkgraaf et al.   CANCER RESEARCH

A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer

(2010) Bassel Fuad El-Rayes et al.   INVESTIGATIONAL NEW DRUGS

Hedgehog Pathway Antagonist 5E1 Binds Hedgehog at the Pseudo-active Site

(2010) Henry R. Maun et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry

(2010) X. Ding et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway

(2010) Elspeth M. Beauchamp et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular Therapy Targeting Sonic Hedgehog and Hepatocyte Growth Factor Signaling in a Mouse Model of Medulloblastoma

(2010) V. Coon et al.   MOLECULAR CANCER THERAPEUTICS

Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector

(2010) J. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

(2010) Shifeng Pan et al.   ACS Medicinal Chemistry Letters

GDC-0449—A potent inhibitor of the hedgehog pathway

(2009) Kirk D. Robarge et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)

(2009) Martin R. Tremblay et al.   JOURNAL OF MEDICINAL CHEMISTRY

Evidence for Allosteric Interactions of Antagonist Binding to the Smoothened Receptor

(2009) C. M. Rominger et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A small molecule that binds Hedgehog and blocks its signaling in human cells

(2009) Benjamin Z Stanton et al.   Nature Chemical Biology

Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma

(2009) Paul A Northcott et al.   NATURE GENETICS

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

(2009) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer

(2009) J M Bailey et al.   ONCOGENE

Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

(2009) R. L. Yauch et al.   SCIENCE

Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor

(2009) H. Wong et al.   XENOBIOTICA

Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy

(2008) John M Pendleton et al.   BMC CANCER

Hhat Is a Palmitoylacyltransferase with Specificity forN-Palmitoylation of Sonic Hedgehog

(2008) John A. Buglino et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A paracrine requirement for hedgehog signalling in cancer

(2008) Robert L. Yauch et al.   NATURE